Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma

Human Pathology

Volumn 44, Issue 12, 2013, Pages 2668-2676

  Munari, Enrico ^a   Fujita, Kazutoshi ^b   Faraj, Sheila ^a   Chaux, Alcides ^a,c   Gonzalez Roibon, Nilda ^a   Hicks, Jessica ^a   Meeker, Alan ^a   Nonomura, Norio ^b   Netto, George J ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c Norte University   (Paraguay)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Mammalian target of rapamycin; mTOR pathway; Prognosis; Upper tract; Urothelial carcinoma

Indexed keywords

FORMALDEHYDE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN S6;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; UROTHELIUM;

MAMMALIAN TARGET OF RAPAMYCIN; MTOR PATHWAY; PROGNOSIS; UPPER TRACT; UROTHELIAL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84888036240     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.07.008     Document Type: Article

References (31)

1. J.D. Raman, J. Messer, J.A. Sielatycki, and C.S. Hollenbeak Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005 BJU Int 107 2011 1059 1064
2. P. Colin, P. Koenig, and A. Ouzzane Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract BJU Int 104 2009 1436 1440
3. M. Roupret, G. Fromont, and A.R. Azzouzi Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma Urology 65 2005 1233 1237
4. L. Schultz, R. Albadine, and J. Hicks Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy Cancer 116 2010 5517 5526
5. C.W. Kinkade, M. Castillo-Martin, and A. Puzio-Kuter Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 2008 3051 3064
6. J. Dancey mTOR signaling and drug development in cancer Nat Rev Clin Oncol 7 2010 209 219
7. M.A. Dominguez-Caceres, J.M. Garcia-Martinez, and A. Calcabrini Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells Oncogene 23 2004 7378 7390
8. G. Viglietto, M.L. Motti, and A. Fusco Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization Cell Cycle 1 2002 394 400
9. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
10. Renal pelvis and ureter. In: Greene FL, Compton C, Fritz AG, Shah J, Winchester DP, eds. AJCC Cancer Staging Atlas. New York: Spinger, 2006, p. 323-8.
11. L. Schultz, A. Chaux, and R. Albadine Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas Am J Surg Pathol 35 2011 1549 1556
12. T.L. Lotan, B. Gurel, and S. Sutcliffe PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
13. S.F. Shariat, R.L. Favaretto, and A. Gupta Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma World J Urol 29 2011 481 486
14. Jeon HG, Jeong IG, Bae J, et al. Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 2010; 76, 513 e517-2.
15. S. Leibl, R. Zigeuner, G. Hutterer, T. Chromecki, P. Rehak, and C. Langner EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology APMIS 116 2008 27 32
16. C. Langner, G. Rupar, and S. Leibl Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression Virchows Arch 448 2006 325 330
17. W. Feng, R.E. Brown, and C.D. Trung Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma Ann Clin Lab Sci 38 2008 195 209
18. T.R. Hartman, E. Nicolas, and A. Klein-Szanto The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis Oncogene 28 2009 1594 1604
19. A.J. Pantuck, D.B. Seligson, and T. Klatte Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2007 2257 2267
20. J.J. Mansure, R. Nassim, S. Chevalier, J. Rocha, E. Scarlata, and W. Kassouf Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer Cancer Biol Ther 8 2009 2339 2347
21. E. Seront, S. Rottey, and B. Sautois Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers Ann Oncol 23 2012 2663 2670
22. F.M. Platt, C.D. Hurst, C.F. Taylor, W.M. Gregory, P. Harnden, and M.A. Knowles Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer Clin Cancer Res 15 2009 6008 6017
23. L.D. Harris, J. De La Cerda, and T. Tuziak Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray Mol Carcinog 47 2008 678 685
24. A. Chaux, E. Comperat, and J. Varinot High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection Urology 81 2013 116 122
25. S. Bose, S. Chandran, J.M. Mirocha, and N. Bose The Akt pathway in human breast cancer: a tissue-array-based analysis Mod Pathol 19 2006 238 245
26. L.I. Yoo, D.W. Liu, S. Le Vu, R.T. Bronson, H. Wu, and J. Yuan Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner Cancer Res 66 2006 1929 1939
27. G. Lughezzani, M. Sun, and P. Perrotte Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database Urology 75 2010 321 327
28. G. Lughezzani, C. Jeldres, and H. Isbarn A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma Urology 75 2010 118 124
29. G. Novara, K. Matsumoto, and W. Kassouf Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study Eur Urol 57 2010 1064 1071
30. C.H. Sun, Y.H. Chang, and C.C. Pan Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder Histopathology 58 2011 1054 1063
31. R.L. Camp, V. Neumeister, and D.L. Rimm A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers J Clin Oncol 26 2008 5630 5637